Abstract
We thank Dr. Kakiuchi and his colleague for their comments on our article, entitled Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease –a systematic review with meta-analysis [1]. Tumor necrosis factor-α (TNF) antagonists have historically been used as the first line of biological therapy for moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD) due to their first development and approval. However, several factors necessitate considerations of alternative treatment options, including contraindications towards TNF antagonists, as approximately two thirds of patients either do not attain or maintain remission one year after TNF antagonist initiation, [2,3] as well as a lower efficacy of subsequent biological therapies after exposure to TNF antagonists [4].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
